Trials / Unknown
UnknownNCT02505113
Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 1 Year – 80 Years
- Healthy volunteers
- Not accepted
Summary
To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein.
Detailed description
To observe the etiology, diagnosis, management and prognosis of cavernous transformation of portal vein. We perform Montelukast (10mg, q.d., p.o.) fot the treatment of symptomatic cavernous transformation of portal vein and to observe the efficacy such as the decrease of the volume of ascites and hydrothorax.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Montelukast | Montelukast (10mg, q.d., p.o.) |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2020-12-01
- First posted
- 2015-07-22
- Last updated
- 2015-10-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02505113. Inclusion in this directory is not an endorsement.